Natera Reports Third Quarter 2026 Financial Results
Natera, Inc. (NTRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Natera Reports Third Quarter 2026 Financial Results AUSTIN, Texas, November 5, 2026 /BUSINESS WIRE/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30,
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The raised guidance could attract new buying interest, but investors should monitor cash burn and debt levels.
Market read
First report of Natera's quarterly results and raised guidance, offering fresh trading insight.
What to watch
Higher operating expenses and ongoing net losses may temper enthusiasm.
Natera Reports Third Quarter 2026 Financial Results
Third-quarter revenue increased 34.1%, test volume increased 22.3%, oncology test volume increased 60.9%, and the company raised its 2026 annual revenue guidance. Gross margin was slightly below the prior-year level and Natera continued to report an operating loss and net loss.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenues, three months ended September 30, 2026GAAP | $794M | – | 34.1% |
| Product revenues, three months ended September 30, 2026GAAP | $790.0M | – | – |
| Licensing and other revenues, three months ended September 30, 2026GAAP | $4M | – | – |
| Gross profit, three months ended September 30, 2026GAAP | $513.5M | – | – |
| Gross margin, three months ended September 30, 2026GAAP | 64.7% | – | – |
| Non-GAAP gross margin, three months ended September 30, 2026, excluding changes in estimates in revenue accrualsnon-GAAP | increased by approximately 1.4% sequentially | increased by approximately 1.4% sequentially | – |
| Change in estimates in revenue accruals, three months ended September 30, 2026GAAP | approximately $32.3 million | – | – |
| Gross-margin increase from changes in estimates, three months ended September 30, 2026GAAP | 1.5% | – | – |
| Tests processed, third quarter of 2026other | approximately 1,093,100 tests | – | 22.3% |
| Tests accessioned, third quarter of 2026other | approximately 1,080,300 tests | – | – |
| Tests reported, third quarter of 2026other | approximately 1,024,800 tests | – | 23.0% |
| Tests reported in laboratory, third quarter of 2026other | approximately 1,012,100 tests | – | – |
| Oncology tests processed, third quarter of 2026other | approximately 339,500 oncology tests | – | 60.9% |
| Clinical MRD oncology units, third quarter of 2026other | grew 32,700 units | grew 32,700 units | – |
| Cost of product revenues, three months ended September 30, 2026GAAP | $279.6M | – | – |
| Cost of licensing and other revenues, three months ended September 30, 2026GAAP | $871K | – | – |
| Research and development expenses, three months ended September 30, 2026GAAP | $242.4M | – | – |
| Selling, general and administrative expenses, three months ended September 30, 2026GAAP | $333.7M | – | – |
| Total operating expenses, third quarter of 2026GAAP | $576.1M | – | 19.5% |
| Amortization of acquired intangible assets, third quarter of 2026GAAP | $5.7M | – | – |
| Total cost and expenses, three months ended September 30, 2026GAAP | $862.3M | – | – |
| Loss from operations, third quarter of 2026GAAP | $68.3M | – | – |
| Interest expense, three months ended September 30, 2026GAAP | $903K | – | – |
| Interest and other income, net, three months ended September 30, 2026GAAP | $9.61M | – | – |
| Loss before income taxes, three months ended September 30, 2026GAAP | $59.61M | – | – |
| Income tax expense, three months ended September 30, 2026GAAP | $299K | – | – |
| Net loss, third quarter of 2026GAAP | $59.9M | – | – |
| Net loss per share, basic and diluted, third quarter of 2026GAAP | ($0.42) per diluted share | – | – |
| Weighted-average shares used in computing basic and diluted net loss per share, third quarter of 2026GAAP | 144.1M | – | – |
| Total revenues, nine months ended September 30, 2026GAAP | $2.24B | – | – |
| Product revenues, nine months ended September 30, 2026GAAP | $2.23B | – | – |
| Licensing and other revenues, nine months ended September 30, 2026GAAP | $11.60M | – | – |
| Cost of product revenues, nine months ended September 30, 2026GAAP | $791.4M | – | – |
| Cost of licensing and other revenues, nine months ended September 30, 2026GAAP | $2.44M | – | – |
| Research and development expenses, nine months ended September 30, 2026GAAP | $681.2M | – | – |
| Selling, general and administrative expenses, nine months ended September 30, 2026GAAP | $988.8M | – | – |
| Amortization of acquired intangible assets, nine months ended September 30, 2026GAAP | $17.12M | – | – |
| Total cost and expenses, nine months ended September 30, 2026GAAP | $2.48B | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | $237.6M | – | – |
| Net loss, nine months ended September 30, 2026GAAP | $212.0M | – | – |
| Net loss per share, basic and diluted, nine months ended September 30, 2026GAAP | $(1.48) | – | – |
| Cash, cash equivalents and restricted cash, September 30, 2026GAAP | $1.10B | increased by approximately $5.7 million | – |
| Total outstanding debt balance, September 30, 2026GAAP | $80.3M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Product revenues, three months ended September 30, 2026The release cited an increase in volume and average selling price improvements for the increase in revenues. | $790.0M | – | – |
| Licensing and other revenues, three months ended September 30, 2026No separate driver was provided. | $4M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
2026 outlook
- Revenue$3.005 billion to $3.035 billion
- Gross marginapproximately 64% to 66%
- NoteSelling, general and administrative costs: approximately $1.225 billion to $1.300 billion
- NoteResearch and development costs: $825 million to $925 million
- NoteCash flow to be positive
What drove it
- Revenue growth was driven by an increase in volume and average selling price improvements.
- Oncology test volume increased 60.9% to approximately 339,500 oncology tests.
- Clinical MRD oncology units grew 32,700 units over the second quarter of 2026.
- The increase in operating expenses was primarily driven by headcount growth to support new product offerings and increases in clinical trial expenses.
- Gross profit reflected higher revenues and continued progress in reducing cost of revenues, offset by a smaller benefit from changes in estimates.
Concerns
- GAAP gross margin was 64.7%, compared to 64.9% in the third quarter of 2025.
- Natera reported a loss from operations of $68.3 million and a net loss of $59.9 million in the third quarter of 2026.
- The benefit to gross margin from changes in estimates was 1.5%, compared to 3.6% in the third quarter of 2025.
- Accounts receivable, net, was $471,354 (in thousands) at September 30, 2026, compared to $296,528 (in thousands) at December 31, 2025.
What to watch
- Execution against 2026 total revenue guidance of $3.005 billion to $3.035 billion.
- Whether gross margin remains within the approximately 64% to 66% 2026 outlook range.
- Progress toward the outlook for positive cash flow.
- Oncology test volume and clinical MRD oncology unit growth.
- Selling, general and administrative costs of approximately $1.225 billion to $1.300 billion and research and development costs of $825 million to $925 million.
Balance sheet and cash flow
- Cash, cash equivalents and restricted cash were $1,097.2 million at September 30, 2026, compared to $1,076.1 million as of December 31, 2025.
- Cash increased by approximately $5.7 million as of September 30, 2026 compared to June 30, 2026.
- Total outstanding debt balance was $80.3 million as of September 30, 2026, including accrued interest under the line of credit with UBS at a variable interest rate of 30-day SOFR plus 50 bps.
- Accounts receivable, net, was $471,354 (in thousands) at September 30, 2026, compared to $296,528 (in thousands) at December 31, 2025.
- Inventory was $91,704 (in thousands) at September 30, 2026, compared to $68,443 (in thousands) at December 31, 2025.
Analysis
Natera delivered $794.0 million of third-quarter revenue, up 34.1% from $592.2 million in the third quarter of 2025. The release attributed the increase to higher volume and average selling price improvements. Tests processed increased 22.3% to approximately 1,093,100, while tests reported increased 23.0% to approximately 1,024,800. Oncology tests processed increased 60.9% to approximately 339,500, and clinical MRD oncology units grew 32,700 units over the second quarter of 2026.
Profitability improved in dollar terms but remained negative. Gross profit was $513.5 million, while GAAP gross margin was 64.7%, compared with 64.9% in the prior-year quarter. The company said gross profit benefited from higher revenue and cost-of-revenue reduction efforts, offset by a smaller benefit from changes in estimates. Changes in estimates increased gross margin by 1.5% in the quarter, versus 3.6% in the comparable 2025 period. Excluding revenue-accrual estimate changes, non-GAAP gross margin increased by approximately 1.4% sequentially.
Operating expenses were $576.1 million, up 19.5% from $482.0 million, primarily due to headcount supporting new product offerings and higher clinical trial expenses. Research and development expenses were $242,433 (in thousands), selling, general and administrative expenses were $333,656 (in thousands), and acquired-intangible amortization was $5.7 million. Loss from operations narrowed to $68.3 million from $97.6 million, while net loss narrowed to $59.9 million, or ($0.42) per diluted share, from $87.5 million, or ($0.64) per diluted share.
Liquidity was $1,097.2 million of cash, cash equivalents and restricted cash at September 30, 2026, an increase of approximately $5.7 million from June 30, 2026. Total outstanding debt was $80.3 million. Natera raised annual revenue guidance by $140 million at the midpoint to $3.005 billion to $3.035 billion and retained a gross-margin outlook of approximately 64% to 66%. The company also expects cash flow to be positive, with selling, general and administrative costs of approximately $1.225 billion to $1.300 billion and research and development costs of $825 million to $925 million.
Not in the filing
stated, not guessed- Prior-release outlook for formal actual-versus-prior-guidance comparison
- Operating cash flow for the reported quarter and nine-month period
- Free cash flow for the reported quarter and nine-month period
- Share repurchases
- Dividend declaration or payment
- Non-GAAP net income or loss
- Non-GAAP EPS
- Operating segment revenue disclosure
- Tax-rate guidance
- Quarterly GAAP total revenue prior-quarter comparison
- Quarterly GAAP gross-margin percentage change versus the prior year
- Named executive quotations
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Natera's Q3 2026 earnings release includes revenue growth, test volume increases, and a raised 2026 revenue outlook.
Ticker impact
Natera raised guidance for 2026 revenue to $3.005B-$3.035B after reporting Q3 2026 results.
likely upward pressure as the market prices in the raised guidance
The company disclosed a material increase in revenue outlook, which typically supports a price rally.
Market effects
Positive for the precision medicine and cell‑free DNA sector as Natera's growth signals demand.
U.S. biotech investors may see a boost.
Limited to biotech and healthcare investors worldwide.
Counterpoint
If the guidance raise is already priced in, the stock could face a short‑term pullback.
Key entities
- companyNatera, Inc.
Provider of cell‑free DNA diagnostics.



